美國家庭壽險 (AFL) 2023 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning and welcome to the Aflac Inc. Second Quarter 2023 Earnings Call. (Operator Instructions) Please note that this event is being recorded today. I would now like to turn the conference over to David Young, Vice President of Investor Relations. Please go ahead.

    早安,歡迎參加 Aflac Inc. 2023 年第二季財報電話會議。(接線員指示)請注意,本活動今日將進行錄音。我現在要將會議交給投資人關係副總裁 David Young。請開始。

  • David Young

    David Young

  • Thank you, Joe. Good morning and welcome. This morning, we will be hearing remarks about the quarter related to our operations in Japan and the United States from Dan Amos, Chairman and CEO of Aflac Incorporated. Fred Crawford, President and COO of Aflac Incorporated, will touch briefly on conditions in the quarter and discuss key initiatives; and Brad Dyslin, Global Chief Investment Officer, President of Aflac Global Investments, will provide an update on the investments.

    謝謝你,Joe。早安,歡迎各位。今天上午,我們將聽取 Aflac Incorporated 董事長兼執行長 Dan Amos 就本季日本與美國營運發表談話。Aflac Incorporated 總裁兼營運長 Fred Crawford 將簡要說明本季狀況並討論關鍵倡議;而全球投資長、Aflac Global Investments 總裁 Brad Dyslin 將提供投資最新進展。

  • Yesterday, after the close, we posted our earnings release and financial supplement to investors.aflac.com. We also posted under financials on the same site updated slides of investment details related to our commercial real estate and middle market loans. In addition, Max Broden, Executive Vice President and CFO of Aflac Incorporated, provided his quarterly video update, addressing our financial results and current capital and liquidity. Max will also be joining us for the Q&A segment of this call, along with the following members of our executive management in the U.S.: Virgil Miller, President of Aflac U.S.; Al Riggieri, Global Chief Risk Officer and Chief Actuary; June Howard, Chief Accounting Officer; and Steve Beaver, CFO of Aflac U.S. We are also joined by members of our executive management team from Aflac Life Insurance Japan; Charles Lake, Chairman and Representative Director, President of Aflac International; Masatoshi Koide, President and Representative Director; Todd Daniels, Director and CFO; Koichiro Yoshizumi, Executive Vice President and Director of Sales and Marketing and Alliance Strategy.

    昨日收盤後,我們已將財報新聞稿與財務補充資料發布於 investors.aflac.com。我們也在同一網站的財務(financials)欄位,更新並上傳了與商用不動產及中型市場貸款相關的投資細節投影片。此外,Aflac Incorporated 執行副總裁兼財務長 Max Broden 提供了季度影片更新,說明我們的財務結果以及目前的資本與流動性。Max 也將與我們一同參與本次電話會議的問答環節,並與以下美國執行管理團隊成員共同出席:Aflac U.S. 總裁 Virgil Miller;全球風險長兼總精算師 Al Riggieri;會計長 June Howard;以及 Aflac U.S. 財務長 Steve Beaver。我們也邀請到 Aflac 生命保險日本(Aflac Life Insurance Japan)的執行管理團隊成員:Aflac International 董事長兼代表董事、總裁 Charles Lake;總裁兼代表董事 Masatoshi Koide;董事兼財務長 Todd Daniels;以及銷售與行銷暨聯盟策略執行副總裁兼董事 Koichiro Yoshizumi。

  • Before we begin, some statements in this teleconference are forward-looking within the meaning of federal securities laws. Although we believe these statements are reasonable, we can give no assurance that they will prove to be accurate because they are prospective in nature. Actual results could differ materially from those we discuss today. We encourage you to look at our annual report on Form 10-K for some of the various risk factors that could materially impact our results. As I mentioned earlier, the earnings release is available on investors.aflac.com and includes reconciliations of certain non-U.S. GAAP measures.

    在開始之前,本次電話會議中的部分陳述依聯邦證券法之定義屬於前瞻性陳述。雖然我們相信這些陳述是合理的,但由於其具有前瞻性,我們無法保證其將被證實為準確。實際結果可能與我們今天討論的內容有重大差異。我們建議您參閱我們的 Form 10-K 年度報告,以了解可能對我們業績造成重大影響的各項風險因素。如我先前所提,財報新聞稿可於 investors.aflac.com 取得,並包含若干非美國 GAAP 衡量指標的調節表。

  • I'll now hand the call over to Dan. Dan?

    我現在把電話交給 Dan。Dan?

  • Daniel Paul Amos - Chairman & CEO

    Daniel Paul Amos - Chairman & CEO

  • Thank you, David and good morning. Glad you joined us. Reflecting on the second quarter of 2023, our management team, employees and sales distribution have continued to work tirelessly as dedicated stewards of our business. This has allowed us to be there for the policyholders when they need us most, just as we promised.

    謝謝你,David,早安。很高興各位加入我們。回顧 2023 年第二季,我們的管理團隊、員工與銷售通路持續不懈地努力,作為企業的盡責管理者。這讓我們能在保戶最需要我們的時候陪伴在旁,正如我們所承諾的。

  • Aflac Incorporated delivered very strong earnings for both the quarter and the first 6 months. We remain actively focused on numerous initiatives in the United States and Japan around new products, distribution strategies to set the stage for future growth.

    Aflac Incorporated 在本季以及前 6 個月都交出非常強勁的獲利表現。我們仍積極聚焦於美國與日本的多項倡議,包括新產品與通路策略,為未來成長奠定基礎。

  • Looking at the operation in Japan, we have continued our rollout of our WINGS cancer insurance and refreshed WAYS and child endowment policies. By introducing new refreshed products, we position our distribution channels for success as Japan makes great strides in recovering from the pandemic.

    就日本營運而言,我們持續推動 WINGS 癌症保險的上市推廣,並更新 WAYS 與兒童養老(child endowment)保單。透過推出全新且更新的產品,我們讓各通路在日本大步從疫情中復甦之際,能更具成功條件。

  • I am very pleased with our new sales premium increase of a 26.6% increase in Japan. This reflects a 60% increase in cancer insurance sales versus the second quarter of 2022 and a significant contributor from Japan Post Company and Japan Post Insurance, which began selling our new cancer product in early April.

    我對日本新契約保費成長 26.6% 感到非常滿意。這反映出相較 2022 年第二季,癌症保險銷售成長 60%,其中日本郵政公司(Japan Post Company)與日本郵政保險(Japan Post Insurance)貢獻顯著,兩者於 4 月初開始銷售我們新的癌症產品。

  • I'm also pleased to see improvements in our sales through agencies and our other strategic alliance, Daido Life and Dai-ichi Life. We also continue to gain new customers through WAYS and child endowment while also increasing opportunities to sell our third sector products, which Fred will address in a moment.

    我也很高興看到我們透過代理店以及其他策略聯盟夥伴(大同生命與第一生命)的銷售有所改善。我們也持續透過 WAYS 與兒童養老產品獲得新客戶,同時增加銷售第三領域產品的機會,Fred 稍後會談到。

  • Thus far, our product strategy has served us well and I'm encouraged by our progress as we prepare for the anticipated mid-September launch of our new medical product. In addition to our products, we know how important it is for us to be where the customers want to buy insurance. Our extensive network of distribution channels, including agencies, alliance partners and banks allow us more opportunities to help provide financial protection to Japanese consumers as we are working hard to support each channel.

    迄今為止,我們的產品策略對我們很有助益;在為預計於 9 月中旬推出的新醫療產品做準備之際,我對我們的進展感到鼓舞。除了產品之外,我們也深知,對我們而言,出現在客戶想要購買保險的地方有多重要。我們廣泛的通路網絡,包括代理店、聯盟夥伴與銀行,讓我們有更多機會為日本消費者提供財務保障;我們也正努力支持每一個通路。

  • Turning to the U.S. I remain encouraged by the continued productivity improvements of our agents and the contribution from growth initiatives. We continue to see success in our efforts to reengage our veteran associates. At the same time, we are seeing strong growth through brokers.

    轉向美國市場,我仍對我們業務員生產力持續改善,以及成長倡議所帶來的貢獻感到鼓舞。我們在重新凝聚資深夥伴(veteran associates)的努力上持續看到成效。同時,透過經紀通路(brokers)也呈現強勁成長。

  • I'm very excited at our cancer protection assurance policy, which provides enhanced benefits at no additional cost. We know that when people experience the value of our products, it increases persistency, which benefits our policyholders and lowers our expenses. I believe that the need for the products and solutions we offer is strong or stronger than it has ever been before in both Japan and the United States.

    我對我們的癌症保障保證保單(cancer protection assurance policy)感到非常振奮,該保單在不增加任何成本的情況下提供更強化的給付。我們知道,當人們體驗到我們產品的價值時,保單持續率(persistency)會提高,這既有利於保戶,也能降低我們的費用。我相信,無論在日本或美國,對我們所提供的產品與解決方案的需求都很強,甚至比以往任何時候都更強。

  • We are leveraging every opportunity and avenue to share this message with consumers. As always, we are committed to prudent liquidity and capital management. We continue to generate strong investment results while remaining in a defensive position as we monitor evolving economic conditions.

    我們正把握每一個機會與管道,向消費者傳達這個訊息。一如既往,我們致力於審慎的流動性與資本管理。我們在持續創造強勁投資成果的同時,也維持防禦性部位,以因應並監測不斷演變的經濟情勢。

  • In addition, we have taken proactive steps in recent years to defend cash flow and deployable capital against the weakening yen. We remain committed to extending our track record of annual dividend increases, supported by the strength of our capital and cash flows. At the same time, we remain in the market repurchasing shares with a tactical approach focused on integrating the growth investments we have made in our platform to improve our strength and leadership position.

    此外,近年來我們已採取主動措施,以因應日圓走弱對現金流與可運用資本(deployable capital)的影響。我們仍致力於延續每年提高股利的紀錄,並以我們強健的資本與現金流作為支撐。同時,我們仍在市場上以策略性方式回購股份,重點在於整合我們在平台上所做的成長投資,以提升我們的實力與領導地位。

  • Overall, I think we can say that it's been a very strong quarter, especially with the vast number of factors that are in our favor. Aflac Japan had a strong quarter of sales as we executed product and distribution strategy. Aflac U.S. continued to build on its momentum as it nears pre-pandemic sales level.

    整體而言,我認為可以說這是一個非常強勁的季度,尤其是在有大量有利因素支持的情況下。Aflac Japan 在執行產品與通路策略方面帶動了強勁的銷售表現。Aflac U.S. 也在接近疫情前銷售水準之際,持續累積動能。

  • Pretax profit margins remained very strong in Japan at 30.4% and in the U.S. at 22.2%, whereas our capital ratios remained very strong and our quarterly share repurchase was like last quarter, one of the biggest in the company's history.

    日本的稅前利潤率維持在非常強勁的 30.4%,美國則為 22.2%;同時,我們的資本比率仍然非常強健,而本季的股票回購規模與上季相同,為公司史上最大規模之一。

  • So with that, I'll turn the program over to Fred. Fred?

    那麼,接下來我把議程交給 Fred。Fred?

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • Thank you, Dan. Let me begin by briefly commenting on conditions in Japan. As Dan commented on, our revised cancer product, which we refer to as WINGS, is doing well, now introduced in the Japan Post Group. Having rolled out WINGS in Japan Post, we are now at full strength with this refreshed product in all channels. Our entire cancer platform, including in-force policyholders is now supported by our (inaudible) cancer consultation services.

    謝謝你,Dan。讓我先簡要評論日本的狀況。如 Dan 所提到的,我們修訂後的癌症產品(我們稱之為 WINGS)表現良好,現已在日本郵政集團推出。隨著 WINGS 在日本郵政完成上線,我們已在所有通路全面到位,推出這項更新產品。我們整體癌症平台(包括既有在保保戶)目前也由我們的(聽不清)癌症諮詢服務所支援。

  • This platform provides concierge care to cancer policyholders connecting them with noninsurance services. In dialogue with key alliance and distribution partners, we continue to receive feedback that this platform is a differentiator in the marketplace. From a data perspective, our market research has shown a positive and meaningful impact to our Net Promoter Scores.

    此平台為癌症保戶提供禮賓式照護(concierge care),協助他們連結保險以外的服務。在與主要聯盟與通路夥伴的對話中,我們持續收到回饋,認為此平台是市場上的差異化因素。從數據角度來看,我們的市場研究顯示,該平台對我們的淨推薦值(Net Promoter Scores)帶來正向且具意義的影響。

  • The sale of WAYS and child endowment continues to deliver on our strategy of attracting younger and new policyholders, along with cross-sell performance. Since the launch of our refreshed WAYS product, approximately 80% of sales are to younger customers below the age of 50. This cohort of younger buyers has driven a concurrent third sector sales rate of approximately 50%.

    WAYS 與兒童養老產品的銷售持續落實我們的策略:吸引更年輕與新的保戶,同時帶動交叉銷售表現。自我們更新版 WAYS 產品推出以來,約 80% 的銷售來自 50 歲以下的年輕客群。這群年輕買家也帶動了約 50% 的同步第三領域銷售率。

  • Looking forward, we anticipate launching our new medical product mid-September. As mentioned last quarter, this product design has been simplified to appeal to both younger policyholders with basic needs and older or existing policyholders who desire upgrade in coverage.

    展望未來,我們預期於 9 月中旬推出新的醫療產品。如同上季所提,該產品設計已予以簡化,以同時吸引需求較基本的年輕保戶,以及希望提升保障的年長或既有保戶。

  • As we move through the natural product renewal cycles, we believe simplifying our products is key to driving sales productivity, attracting new and younger policyholders and lowering our operating costs.

    隨著我們進入自然的產品更新週期,我們相信,簡化產品是推動銷售生產力、吸引新的與更年輕保戶,以及降低營運成本的關鍵。

  • Turning to operations. We are pleased with our expense ratio traveling below 20% in the first half of the year and in the face of continued revenue pressure. We are actively working to increase digital adoption, focused on new business applications, customer self-service and claims. As we look forward, we anticipate increased levels of investment to drive digital adoption with the goal of remaining competitive by lowering our long-term operating expenses on a per policy basis.

    接著談營運。我們對今年上半年在持續的營收壓力下,費用率仍能降至 20% 以下感到滿意。我們正積極推動數位採用,聚焦於新業務申請、客戶自助服務與理賠。展望未來,我們預期將提高投資水準以推動數位採用,目標是在每張保單的長期營運費用下降的同時,維持競爭力。

  • Turning to the U.S. Our second quarter results followed a similar pattern as the first quarter with individual dental and vision, group life and disability and consumer markets, all contributing to sales growth. Group voluntary sales has been down modestly from a strong 2022. However, we remain encouraged by the level of quoting activity that we believe positions us for a stronger second half of the year.

    接著談美國。我們第二季的結果與第一季呈現相似型態:個人牙科與視力、團體壽險與失能,以及消費者市場,皆對銷售成長有所貢獻。團體自願性保險銷售較 2022 年的強勁表現小幅下滑。然而,我們仍對報價活動的水準感到鼓舞,並相信這使我們有望在下半年表現更強。

  • Our growth platforms of dental and vision, group life and disability and consumer markets are beginning to have a more material impact on performance. In aggregate, sales produced by these platforms are up over 50%, albeit, of a smaller and building base. With the build largely behind us, we are focused on driving scale, stabilizing new platforms and leveraging our ability to bundle core voluntary products as we work with brokers on larger groups.

    我們的成長平台——牙科與視力、團體壽險與失能,以及消費者市場——開始對績效產生更實質的影響。整體而言,這些平台帶來的銷售成長超過 50%,儘管基期較小且仍在擴大中。隨著建置工作大致完成,我們將重點放在推動規模化、穩定新平台,並在與經紀人合作承作更大型團體時,運用我們將核心自願性產品打包銷售的能力。

  • We are absorbing a pace of investment in growth platforms that pressures our expense ratio but naturally precedes revenue development. This is particularly the case in our group life and disability business, which is more capital intensive. As we settle into operating these platforms, we are also refining our approach to drive expense efficiencies and a long-term path to profitability. In some cases, making decisions around business we choose to exit and opportunities we aggressively pursue.

    我們正吸收對成長平台的投資節奏,這會對費用率造成壓力,但也自然先於營收發展。這在我們的團體壽險與失能業務上尤其明顯,因其資本密集度較高。隨著我們逐步穩定這些平台的營運,我們也在精進方法以提升費用效率,並建立通往長期獲利的路徑。在某些情況下,這也意味著要就我們選擇退出的業務,以及我們積極追求的機會做出決策。

  • Last quarter, we commented on our renewed focus on product development in the U.S. Our refreshed cancer product is up roughly 23% and still in the early stages of rollout. Of all the critical illnesses, cancer remains the most frequent and devastating to families and their financial security and we have high expectations for this product.

    上季我們提到在美國重新聚焦產品開發。我們更新版的癌症產品成長約 23%,且仍處於推廣初期。在所有重大疾病中,癌症仍是最常見且對家庭與其財務安全打擊最沉重的一種,我們對這項產品抱持高度期待。

  • Last week, we announced a new group voluntary term life product which is part of an important effort to increase our overall worksite life sales. We have lagged in terms of life sales and see this product line as an area where we have market share opportunity.

    上週,我們宣布推出新的團體自願性定期壽險產品,這是提升我們整體職場壽險銷售的重要努力之一。我們在壽險銷售方面一直相對落後,並將此產品線視為具備提升市占率的機會領域。

  • Like cancer insurance, this is a product that should contribute to improved persistency. We are pleased to see a return to earned premium growth in the U.S. and modest recovery in persistency. We continue to drive utilization through wellness campaigns and benefit endorsements to in-force policies with the objective of improved sales, persistency and driving core revenue growth.

    如同癌症保險,這也是一項可望提升保單持續率的產品。我們很高興看到美國已賺保費恢復成長,且持續率小幅回升。我們持續透過健康促進活動與對既有保單的給付附加條款來提升使用率,目標是改善銷售與持續率,並推動核心營收成長。

  • Now let me pause. And I'm going to turn the call over to Brad Dyslin, to bring you current on the health of our investment portfolio with a focus on the loan book. Brad?

    現在我先暫停一下。接下來我將把電話交給 Brad Dyslin,請他就我們投資組合的健康狀況,特別是放款組合,向各位更新。Brad?

  • Bradley Eugene Dyslin - Deputy Global CIO, Senior MD, Global Head of Credit & Strategic Investment Opportunities

    Bradley Eugene Dyslin - Deputy Global CIO, Senior MD, Global Head of Credit & Strategic Investment Opportunities

  • Thank you, Fred. During last quarter's call, we provided an update on our loan portfolios with a special focus on our middle market direct lending and real estate mortgage holdings. I am pleased to report that both of these portfolios continue to perform in line with the expectations we shared last quarter.

    謝謝你,Fred。在上一季的電話會議中,我們就放款投資組合提供了更新,並特別聚焦於我們的中型市場直接放款與不動產抵押貸款持有部位。我很高興報告,這兩個投資組合的表現持續符合我們上季所分享的預期。

  • Let me start with commercial real estate. As a reminder, most of our exposure is to transitional properties, where we make short-term floating rate loans to facilitate the asset's repositioning in the local market. TRE comprises $6.4 billion or about 3/4 of our total $8.1 billion commercial mortgage loan portfolio, with the balance held in more traditional longer-term fixed rate loans.

    我先從商用不動產談起。提醒一下,我們的大部分曝險在於過渡型資產(transitional properties),我們提供短期浮動利率貸款,以協助資產在當地市場重新定位。TRE 規模為 64 億美元,約占我們 81 億美元商用抵押貸款投資組合的 3/4,其餘則為較傳統的長期固定利率貸款。

  • Our commercial real estate loan watch list has remained constant at approximately $900 million and consists almost entirely of TRE office properties. The workout process for these loans is complex and negotiations with the properties' owner tend to be very fluid, a dynamic we follow very closely. As a result, our foreclosure watch list gets updated relatively frequently as negotiations with the property owner ebb and flow. However, the total value of these loans has also remained relatively stable with only a modest increase from first quarter.

    我們的商用不動產放款觀察名單維持在約 9 億美元,幾乎全部為 TRE 辦公室資產。這些貸款的處置(workout)流程相當複雜,且與資產所有人的協商往往非常多變,我們也密切追蹤此一動態。因此,隨著與資產所有人的談判進展起伏,我們的法拍觀察名單會相對頻繁更新。不過,這些貸款的總價值也維持相對穩定,僅較第一季小幅增加。

  • As we mentioned last quarter, when the loan foreclosure is likely to occur, we must mark the carrying value of our loan to the fair market value of the underlying property assets. With our average loan-to-value of 65%, this accounting process resulted in a small $11 million of additional reserves in the quarter.

    如同我們上季提到的,當貸款很可能進入法拍時,我們必須將貸款帳面價值調整至其所對應之不動產資產的公允市價。以我們平均 65% 的貸款價值比(LTV)而言,這項會計處理使本季額外提列了小幅的 1,100 萬美元準備。

  • This brings the total amount of additional reserves recognized in the first half of the year to $21 million, which represents about 26 basis points of our $8.1 billion total commercial real estate portfolio. And as the result of property value declines generally in the range of 25% to 40%, price drops that are in line with those of the financial crisis.

    這使得今年上半年認列的額外準備總額達到 2,100 萬美元,約相當於我們 81 億美元商用不動產投資組合的 26 個基點。此係因不動產價值下跌幅度普遍落在 25% 至 40% 的區間,跌幅與金融危機時期相當。

  • If you simply apply a 40% price decline across our entire $900 million watch list, we would expect very manageable additional reserves of $50 million. Once the property goes into foreclosure proceedings, we no longer accrue interest on the loan but instead realize the net operating income from the property. Given the transitional nature of these properties, we will see a decline in net investment income from this change.

    若僅以 40% 的價格跌幅套用到我們整體 9 億美元的觀察名單,我們預期需額外提列的準備約為 5,000 萬美元,仍屬可控。一旦資產進入法拍程序,我們將不再對該貸款計提利息收入,而是改為認列該不動產的淨營運收入。鑑於這些資產的過渡性特質,這項變更將使淨投資收益下降。

  • When considering overall investment performance, we do not expect this to have a material impact to enterprise NII. While we are not immune from the industry pressure in commercial real estate, we remain confident in the quality of the properties supporting our loans. Our strong capital position and ample liquidity allow us to be a patient investor as we manage through the downturn to maximize our overall economics.

    就整體投資表現而言,我們不預期這會對企業層級的淨投資收益(NII)造成重大影響。雖然我們無法完全免於商用不動產產業的壓力,但我們仍對支撐我們貸款的資產品質有信心。我們強健的資本部位與充足的流動性,使我們能以耐心的投資人姿態,在景氣下行期間進行管理,以最大化整體經濟效益。

  • I am pleased to report our portfolio of loans to middle-market companies continues to perform well and is exceeding our expectations for credit losses at this point in the cycle. Recall this is our primary outlet for below investment grade exposure and was purposely built with a quality bias to perform well during difficult periods for credit. Our strategy of allowing only modest levels of first lien leverage on growing companies in noncyclical industries owned by supportive sponsors is delivering strong risk-adjusted returns.

    我也很高興報告,我們對中型市場公司的放款投資組合持續表現良好,且在本輪景氣循環的此階段,其信用損失表現優於我們的預期。請記得,這是我們承接非投資等級曝險的主要管道,並刻意以偏重品質的方式建構,以在信用環境艱困時仍能有良好表現。我們的策略是:對由具支持力的贊助方持有、位於非循環性產業、且仍在成長的公司,只允許適度的第一順位擔保槓桿,這正帶來強勁的風險調整後報酬。

  • Finally, you may have seen the announcement last month that Varagon Capital is being acquired by Man Group, a leading U.K. alternatives asset manager. As part of this transaction, as was announced, we are exiting our equity position in Varagon but will remain a major client. We generated strong returns on this strategic investment realizing over 3x our invested capital in addition to solid performance on the $3 billion of middle market loans Varagon has managed for us the last 3-plus years.

    最後,各位可能已看到上月的公告:Varagon Capital 將被英國領先的另類資產管理公司 Man Group 收購。作為此交易的一部分,如公告所述,我們將退出在 Varagon 的股權部位,但仍會是其主要客戶。我們在這項策略性投資上取得了強勁報酬,實現超過投入資本 3 倍的回報;此外,Varagon 過去 3 年多來為我們管理的 30 億美元中型市場放款也有穩健表現。

  • Varagon has proven to be a great partner and terrific investor and we are excited about their future as part of the Man Group. Our relationship with Varagon and our other current strategic equity partners is a valuable part of our strategy for accessing certain specialized private asset classes that have a strategic role in our portfolio.

    Varagon 已證明是優秀的合作夥伴與出色的投資人,我們也對其加入 Man Group 後的未來感到振奮。我們與 Varagon 以及其他現有策略性股權合作夥伴的關係,是我們策略中相當有價值的一環,有助於我們進入某些專業的私募資產類別,而這些資產在我們的投資組合中具有策略性角色。

  • We continue to invest significant amounts in these high value-add forms of private credit. We look forward to continuing to execute on this strategy and creating additional value through an ownership presence in these important asset classes.

    我們持續在這些高附加價值的私募信貸形式上投入大量資金。我們期待持續執行此一策略,並透過在這些重要資產類別中的持股參與,創造更多價值。

  • Let me turn it back to Fred.

    我把時間交回給 Fred。

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • Thank you, Brad. As Brad noted, we followed a disciplined approach that began with building out our external manager program that matured into taking a minority interest in select managers. These investments have produced strong returns and we intend to expand upon this strategy as opportunities present themselves.

    謝謝你,Brad。如 Brad 所提,我們採取了自律的做法:先建立外部管理人計畫,並逐步成熟到對特定管理人取得少數股權。這些投資帶來了強勁回報,我們也打算在機會出現時擴大此一策略。

  • Market conditions remain volatile as both the U.S. and Japan economies go through a period of transition. Last week featured moves by both the Fed and the BoJ, the U.S. is looking to calm down inflation and avoid recession, while Japan continues to maintain its ultra-loose monetary policy as the economic and inflationary uncertainty remain high.

    由於美國與日本經濟正處於轉型期,市場狀況仍然波動。上週聯準會(Fed)與日本央行(BoJ)皆有動作:美國希望讓通膨降溫並避免衰退;而日本在經濟與通膨不確定性仍高的情況下,持續維持其超寬鬆的貨幣政策。

  • As Max noted in his recorded comments, through investment strategy, hedging and capital engineering, we have greatly reduced our enterprise economic exposure to movements in the yen. In addition, our low asset leverage places us in a naturally strong position to absorb weak or volatile economic conditions and maintain capital deployment plans.

    如 Max 在其預錄評論中所提,透過投資策略、避險與資本工程,我們已大幅降低企業層級對日圓波動的經濟曝險。此外,我們較低的資產槓桿使我們在吸收疲弱或波動的經濟環境、並維持資本部署計畫方面,具備天然的優勢。

  • I'll now turn it back to David to take us to Q&A. David?

    我現在把時間交回給 David,帶我們進入問答環節。David?

  • David Young

    David Young

  • Thank you, Fred. (Operator Instructions) And Joe, we will now take that first question.

    謝謝你,Fred。(接線員指示)Joe,我們現在開始進行第一個問題。

  • Operator

    Operator

  • Our first question will come from Tom Gallagher with Evercore ISI.

    我們的第一個問題將由 Evercore ISI 的 Tom Gallagher 提出。

  • Thomas George Gallagher - Senior MD

    Thomas George Gallagher - Senior MD

  • It was encouraging to see the growth in Japanese sales. I guess the question I have related to it is 2 parts. One is, how do you see the contribution from Japan Post building out? Is that continued gradual slow ramp? Or do you -- are you seeing any signs of stronger acceleration there?

    看到日本銷售成長令人鼓舞。我想我對此相關的問題分成兩部分。第一是,你們如何看待日本郵政(Japan Post)的貢獻逐步建立起來?是持續逐步、緩慢地爬坡嗎?還是你們——你們是否看到那邊有更強勁加速的跡象?

  • And then I guess the follow-up is, while there were good sales, the overall top line in terms of earned premium was a bit soft. So can you talk about your expectations for earned premium and what's weighing on that and not allowing the sales improvement to necessarily translate?

    接著我想追問的是,雖然銷售表現不錯,但就已賺保費(earned premium)而言,整體營收端(top line)有點疲弱。所以你們能否談談對已賺保費的預期,以及是什麼因素在拖累、使得銷售改善未必能轉化反映出來?

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • Let me start by making just a couple of comments and then I'll hand off to some of the folks around the table to contribute. Tom, this is Fred. First, on sales results in Japan Post in the quarter. We -- as you may know or may remember, based on our alliance, we don't comment on some of the specific results coming out of those channels. But what we certainly can say is that the launch of the cancer product in the quarter was the majority contributor to the increase in cancer sales that you saw in our results. For example, in the first quarter, without being launched in Japan Post, our sales were up in cancer around 25% or so. And as Dan mentioned in his comments, in the second quarter, we were up around 60% and you can safely assume the majority contributor of that was from Japan Post.

    我先簡單做幾點評論,然後再請桌邊的幾位同仁補充。Tom,我是 Fred。首先,關於本季日本郵政通路的銷售結果。我們——如你所知或可能記得,基於我們的聯盟合作,我們不會評論來自那些通路的一些具體結果。但我們可以確定地說,本季癌症產品的上市,是你在我們結果中看到癌症銷售增加的主要貢獻來源。舉例來說,在第一季,尚未在日本郵政上市的情況下,我們的癌症銷售仍成長約 25% 左右。而如 Dan 在他的評論中提到,第二季我們成長約 60%,你可以合理地推定其中大部分貢獻來自日本郵政。

  • Your question then is, what about continuation. And our view is that there is still a much more runway in Japan Post over the long term, predominantly as they build efficiency in their distribution channel and more and more agents take on the cancer product and begin producing. So we do think that there's a continuation of upside in Japan Post. However, it is also the case that commonly right when you launch the product, you'll have an immediate jump in sales in the early months, followed by a calming down. But let me just turn to Yoshizumi-san and/or Koide-san, if they'd like to comment or add any color beyond what I just said.

    你的問題接著是,這樣的表現是否會延續。我們的看法是,從長期來看,日本郵政仍有更長的成長跑道,主要在於他們持續提升其分銷通路的效率,並且有越來越多的業務員承作癌症產品並開始產出。因此我們確實認為日本郵政仍有持續上行空間。不過,同時也常見的是,產品剛上市時,前幾個月銷售會立即跳升,之後會趨於平穩。但我先把問題轉給 Yoshizumi 先生和/或 Koide 先生,看看他們是否願意評論或補充一些我剛才所說以外的觀點。

  • Koichiro Yoshizumi - EVP of Sales & Mrkt. and Director of Sales, Mrkt., Alliance Strategy - Aflac Life Insurance Japan

    Koichiro Yoshizumi - EVP of Sales & Mrkt. and Director of Sales, Mrkt., Alliance Strategy - Aflac Life Insurance Japan

  • [Interpreted] This is Yoshizumi. So let me answer your question regarding, JP. Well, let me mention about the new products launched in the Japan Post channel. The cancer product in the Japan Post channel was launched in April. And towards this April timing, we have been conducting trainings to the Japan Post company, the postal company as well as Japan Post Insurance since January throughout their entire nationwide post offices. And we do believe the steady increase of sales by the Japan Post has -- is a result of us conducting these kind of trainings as well as offering our support to them directly after the launch of the product.

    [口譯] 我是 Yoshizumi。那我來回答你關於 JP 的問題。首先我想提一下在日本郵政通路推出的新產品。日本郵政通路的癌症產品是在 4 月上市。而在 4 月這個時間點前後,我們自 1 月起就在全國各地郵局,對日本郵政公司(郵政公司)以及日本郵政保險持續進行培訓。我們也相信,日本郵政銷售的穩定增加——是我們進行這類培訓以及在產品上市後直接提供支援所帶來的成果。

  • And since the second quarter between Japan -- the Japan Post and Aflac, we have been confirming each layer or each level of sales process at the management level and we'll be managing these processes at each level. And what that means is that we will try to identify where the issues are at each management level and we are checking those items on a monthly basis and we are also offering solutions to these issues and solving them on a monthly basis. As a result of all of these, we do believe that cancer sales will gradually increase going forward as well. That's all for me.

    此外,自第二季起,日本郵政與 Aflac 之間,我們在管理層級確認銷售流程的各個層面或各個階段,並將在各層級管理這些流程。這表示我們會嘗試辨識各管理層級的問題所在,並以每月為頻率檢視這些事項;同時也會針對這些問題提出解決方案,並以每月為單位加以解決。基於上述各項作為,我們也相信未來癌症銷售將會逐步增加。我的部分就到這裡。

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • And then Tom, your second question was related to revenue in Japan and how to think about it. Obviously, having to take into account both our reinsurance agreement and paid-up policies. So I'll ask Todd to address that.

    然後 Tom,你的第二個問題與日本的收入以及該如何看待它有關。顯然需要同時考量我們的再保險協議以及繳清保單(paid-up policies)。所以我請 Todd 來回應。

  • James Todd Daniels - Executive VP, Director & CFO of Aflac Life Insurance Japan

    James Todd Daniels - Executive VP, Director & CFO of Aflac Life Insurance Japan

  • Yes, real quick. I think that one thing to remember, when we went to LDTI accounting, we had to move our deferred profit liability from the benefits line to the earned premium line and that's going to create a little bit of noise in that. It's not going to be as stable as it was before. But as Fred said, the reinsurance transaction that we entered into at the beginning of the year caused about JPY 8 billion reduction in earned premium in the quarter. The paid-up impact is also still there and that was again about JPY 8 billion. When you normalize for those 2 factors and considering the DPL, we're still in the right -- in the middle of the range that we gave for guidance for earned premium at approximately minus 1.9%.

    好的,我很快說一下。我想要記得的一點是,當我們採用 LDTI 會計時,我們必須把遞延利潤負債(deferred profit liability, DPL)從給付(benefits)項下移到已賺保費(earned premium)項下,這會在該項目造成一些雜訊;它不會像以前那麼穩定。但如 Fred 所說,我們在年初進行的再保險交易,使本季已賺保費減少約 80 億日圓。繳清(paid-up)的影響也仍然存在,同樣約 80 億日圓。若將這兩項因素正常化並考量 DPL,我們仍落在先前給出的已賺保費指引區間的正中間,約為 -1.9%。

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • And Tom, I would just add as well, if you look at it long term, for us to sort of get to a level where we are replacing the business that is falling off, i.e., get to an earned premium growth of 0, we need to essentially get back for all distribution channels to prepandemic levels in terms of production and also have the Japan Post channel get back to a restored production level.

    而且 Tom,我也補充一點:若從長期來看,為了讓我們達到能夠補回流失業務的水準——也就是讓已賺保費成長回到 0——我們基本上需要所有分銷通路的產能回到疫情前的水準,同時也需要日本郵政通路回到恢復後的產能水準。

  • Operator

    Operator

  • And our next question will come from Alex Scott with Goldman Sachs.

    我們的下一個問題將由高盛(Goldman Sachs)的 Alex Scott 提出。

  • Taylor Alexander Scott - Equity Analyst

    Taylor Alexander Scott - Equity Analyst

  • First one I had for you is on some of the comments that were made in the remarks video that you all post. It was mentioned that the actual to expecteds are continuing to run favorable and what you're seeing in the claims activity and the benefit ratios. And I was just interested what the updated view is on whether that's temporary, associated with utilization levels, potentially being temporarily depressed versus maybe something that you guys have just seen longer term and that you potentially need to adjust in your long-term assumptions?

    我第一個問題是關於你們發布的備註影片(remarks video)中提到的一些評論。裡面提到實際值相對於預期值(actual to expecteds)持續表現有利,以及你們在理賠活動與給付率(benefit ratios)方面所看到的情況。我想了解你們最新的看法:這是否只是暫時性的、與使用率(utilization)水準可能暫時偏低有關?或者這是你們長期觀察到的現象,可能需要調整你們的長期假設?

  • Daniel Paul Amos - Chairman & CEO

    Daniel Paul Amos - Chairman & CEO

  • This is Dan. I'll kind of mention that and let the actuaries, if they want to go into more details, Todd or whoever. But it has continued to run at a lower rate than we have anticipated year after year after year. And we have tried to counter that with different things from increased benefits on certain policies when a new one came out. But for some reason, you're seeing more and more trends to do -- well, we know why, outpatient treatments and things of that nature as we're seeing changes take place, we have to adapt accordingly. But some of the policyholders don't change over policies. And that's something that we continue to monitor and encourage people to do. If you specifically want to talk about U.S., that's a great example. The wellness benefit hadn't been used as much. So we have really encouraged that. We're seeing that improvement and we feel like that will be reflected in a positive manner. I think Virgil might touch on that if he's around to say something. Virgil?

    我是 Dan。我先簡單提一下,若精算團隊想補充更多細節,Todd 或其他人也可以。這個水準年復一年都持續低於我們的預期。我們也嘗試用不同方式來因應,例如在推出新保單時提高某些保單的給付。但不知為何,你看到越來越多的趨勢——嗯,我們知道原因,像是門診治療等這類情況;隨著變化發生,我們必須相應調整。但有些保戶並不會轉換到新保單。這是我們持續監控並鼓勵大家去做的事。如果你特別想談美國,那是個很好的例子。健康促進給付(wellness benefit)過去使用得沒那麼多,所以我們大力鼓勵使用。我們看到改善,也覺得這會以正面的方式反映出來。我想如果 Virgil 在場,他可能會談一下。Virgil?

  • Virgil Raynard Miller - President of Aflac U.S.

    Virgil Raynard Miller - President of Aflac U.S.

  • Thank you, Dan. Yes, utilization continues to be our focus in the U.S. We have launched a series of wellness campaigns, really driving our policyholders to leverage the coverage. I think Fred or Dan mentioned that we've seen over a 22% increase in wellness utilization during that time period, which started about the first quarter of the year. we're going to continue to do that. Our main thing is to drive and demonstrate value. We know that the average American has less than $1,000 in savings out there. So there's a benefit to them to make sure they're prepared for any unexpected medical event and also getting regular checkups will help anyone that gets diagnosed with some catastrophic disease like cancer, it helps them, of course, be able to get the right treatment and save their lives. So we're going to continue to push on that and I expect us to see continued improvement going forward.

    謝謝你,Dan。是的,在美國,使用率(utilization)仍是我們的重點。我們已推出一系列健康促進活動(wellness campaigns),真正推動保戶善用保障。我想 Fred 或 Dan 提到過,自那段期間開始(大約從今年第一季起),我們看到健康促進使用率提升超過 22%。我們會持續推動。我們最主要的目標是推動並展現價值。我們知道一般美國人的儲蓄平均不到 1,000 美元。因此,確保他們為任何突發醫療事件做好準備,對他們是有益的;同時,定期健檢也能幫助任何被診斷出像癌症這類重大疾病的人,當然能夠接受正確治療並挽救生命。所以我們會持續推進,我也預期未來會看到持續改善。

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • And Alex, just to sort of add in terms of utilization. If you think about, U.S. is absolutely out of the pandemic now and you should expect the utilization to sort of get back to sort of a normal level at this point. I think we're still a little bit of a -- where we should expect some rebound on utilization but definitely, the vast majority of the benefits that we offer should run at more normal levels at this point. So what we're doing, as Dan and Virgil alluded to, we are enhancing our products for that because we have not seen utilization bounce back to pre-pandemic levels.

    Alex,另外就使用率再補充一下。若你想,美國現在絕對已走出疫情,你應該預期使用率此時會回到較正常的水準。我認為使用率仍有一些——我們仍應期待一定程度的回升,但可以確定的是,我們提供的絕大多數給付此時應該會在更正常的水準運行。因此,如 Dan 和 Virgil 所提到的,我們正在為此強化產品,因為我們尚未看到使用率回到疫情前的水準。

  • And so why is that? Well, there are some fundamental differences that have happened during the pandemic. There's definitely less usage of emergency rooms that we see in the data, greater use of local facilities. Greater use of outpatient services rather than in-hospital services. All of this leads to lower claims utilization overall for us. If you go to Japan, we continue to see the long-term trends of shorter hospitalization stays, especially as it relates to cancer. We have seen first diagnosis, i.e., diagnosis of cancer bounce back to more normal levels but the surgeries and hospitalization trends are still pretty muted. And we believe that, that's more driven by greater use of outpatient services as well in Japan as well because we see that increase. Overall, the net effect of this is that it leads to a lower benefit ratio overall for us if these trends continue to stay in place.

    那麼,為什麼會這樣呢?嗯,在疫情期間確實出現了一些根本性的差異。從數據來看,急診室的使用量明顯下降,更多改為使用在地醫療機構;門診服務的使用增加,而非住院服務。這些因素整體導致我們的理賠使用量下降。若看日本,我們仍持續看到長期趨勢,也就是住院天數縮短,尤其是在癌症相關方面。我們看到首次診斷(也就是癌症診斷)已回升到較正常的水準,但手術與住院的趨勢仍相當低迷。我們認為這更多是因為日本門診服務的使用也增加了,因為我們確實看到那樣的增幅。整體而言,如果這些趨勢持續存在,淨效果就是我們的整體給付比率會更低。

  • Taylor Alexander Scott - Equity Analyst

    Taylor Alexander Scott - Equity Analyst

  • Got it. Very helpful. A follow-up I had is just on Japanese interest rates. I was interested in just how it affects your strategy in terms of, if you all are thinking through different products that you may emphasize more in a higher rate environment as well as on the investment side, choices you're making between USD investing and yen investing?

    了解。非常有幫助。我有一個追問是關於日本利率。我想了解它如何影響你們的策略:在較高利率環境下,你們是否會思考更著重推廣某些產品?以及在投資端,你們在美元投資與日圓投資之間做選擇時的考量是什麼?

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • I'll let Brad comment on the asset allocation question. I think relative to the business model, as you may know from some of our previous comments, we continue to work on what we would call -- what we call internally our asset formation product strategy in Japan. That's most notably surrounding the WAYS product and refreshment and refinement to the WAYS product, training and development around that product and working with customers and then, of course, an emphasis on cross-selling. What we've also mentioned, Alex, in the past, is that not only has a recent recovery, I'll put recovery in quotes, of course, but recovery in rates in Japan help with supporting those types of products.

    我先請 Brad 回答資產配置的問題。我想就商業模式而言,如同你可能從我們先前的一些評論中所知,我們持續推動我們在日本所稱的——內部稱之為資產形成型產品策略。這最主要圍繞 WAYS 產品,以及對 WAYS 產品的更新與精進、針對該產品的訓練與發展、與客戶共同推動,當然還有對交叉銷售的重點投入。我們過去也提到過,Alex,不僅如此,日本利率近期的回升——我當然要在「回升」上加引號——但日本利率的回升確實有助於支撐這類產品。

  • Also importantly, is building out our reinsurance strategy because there's no question reinsurance is going to play into the long-term viability of those types of products and maintaining economic value as a company. So yes, some rise in rates is supportive of asset formation products and we pay attention to that. But as you can see, there's a long way to go before we would characterize the rate environment as supportive of strong profitability in those products. You still need some heavy engineering, you absolutely are in that business for the cross-sell experience and bringing younger policyholders into the fold that we can cross-sell into the future. Brad, comments on...

    同樣重要的是,建立我們的再保險策略,因為毫無疑問,再保險將影響這類產品的長期可行性,以及公司維持經濟價值的能力。所以,是的,利率上升對資產形成型產品是有支持作用的,我們也會關注。但如你所見,在我們會將利率環境描述為足以支持這些產品強勁獲利之前,仍有很長的路要走。你仍需要大量的產品工程設計;而你投入這項業務,絕對是為了交叉銷售的體驗,以及把較年輕的保戶納入體系,讓我們未來能進一步交叉銷售。Brad,請補充……

  • Bradley Eugene Dyslin - Deputy Global CIO, Senior MD, Global Head of Credit & Strategic Investment Opportunities

    Bradley Eugene Dyslin - Deputy Global CIO, Senior MD, Global Head of Credit & Strategic Investment Opportunities

  • Sure. In terms of investment activity, the rise in yen rates is certainly welcome news. It's been a long time since we've had these kind of levels. But one of the biggest issues we face in Japan is finding attractive spread products and that remains our biggest challenge. We continue to take advantage of those opportunities when we can find them. We have been relatively successful in finding yen credit where we can get an acceptable level of pickup over JGB yields for what we think is a pretty acceptable level of risk. And although rates are definitely -- the rise in rates is definitely welcome, it still pales in comparison to what we're able to get in some of the dollar assets. So we'll continue to always be active there but you shouldn't expect to see a big wholesale change in strategy, at least not yet.

    好的。就投資活動而言,日圓利率上升當然是令人樂見的消息。我們已經很久沒有看到這樣的水準了。但我們在日本面臨的最大問題之一,是尋找具吸引力的利差型商品,而這仍是我們最大的挑戰。我們會在能找到機會時持續把握。我們在尋找日圓信用資產方面相對成功,能在我們認為風險相當可接受的前提下,取得相對於日本國債(JGB)殖利率的合理利差提升。雖然利率上升確實令人歡迎,但與我們在部分美元資產上能取得的水準相比仍相形見絀。因此我們會持續保持活躍,但你不應預期策略會出現大幅、全面性的改變,至少目前還不會。

  • Operator

    Operator

  • Our next question will come from Suneet Kamath with Jefferies.

    下一個問題來自 Jefferies 的 Suneet Kamath。

  • Suneet Laxman L. Kamath - Equity Analyst

    Suneet Laxman L. Kamath - Equity Analyst

  • I wanted to go back to some of the comments that you're making on utilization, both in Japan and the U.S. It seems like things are moving in the right direction. My question is, how quickly do these benefits get reflected in your financial statements under this kind of remeasurement concept in LDTI? My thought was, historically, these impacts would take a while to kind of feather in but I'm wondering if under LDTI, does this get reflected in your financials much faster?

    我想回到你們對使用量(utilization)的幾點評論,包含日本與美國。看起來情況正朝正確方向發展。我的問題是:在 LDTI 這種重新衡量(remeasurement)的概念下,這些給付面的改善會多快反映在你們的財務報表中?我的想法是,過去這些影響通常需要一段時間才會逐步反映,但我想確認在 LDTI 之下,是否會更快反映到財務數字?

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • Suneet, they definitely come into our financials faster than they've done historically and it's because we rerun these remeasurements each quarter and reset the net premium ratio for our forward reserves. So therefore, you get it into the results much quicker.

    Suneet,這些確實會比過去更快進入我們的財務結果,原因是我們每季都會重新執行這些重新衡量,並重設用於未來準備金的淨保費比率(net premium ratio)。因此,你會更快在結果中看到反映。

  • Suneet Laxman L. Kamath - Equity Analyst

    Suneet Laxman L. Kamath - Equity Analyst

  • And I guess, where are we with that now? I mean are we kind of -- should we expect some of these benefits that you saw here in 2Q to persist going forward? Or is it more you've baked in these lower utilization trends. And so going forward, we need to see them decline even more to get incremental benefits?

    那我想問,目前進展到哪裡了?也就是說,我們是否應該預期你們在第二季看到的這些好處會在未來持續?還是說你們已經把這些較低的使用量趨勢納入假設了,因此往後我們需要看到使用量進一步下降,才會有額外的增量效益?

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • We true up our reserves for a recent experience and to our best estimate. And then going forward, what that means is that, for you to get lower reserves in the future, you need to have an improved trend. If the utilization stays at this level, our reserves are adequate. If you were to have worsening trends, the opposite would then occur.

    我們會依近期經驗與我們的最佳估計來調整(true up)準備金。往後的意涵是:若你要在未來看到更低的準備金,就需要趨勢進一步改善。如果使用量維持在目前水準,我們的準備金是充足的;若趨勢惡化,則會出現相反的情況。

  • Suneet Laxman L. Kamath - Equity Analyst

    Suneet Laxman L. Kamath - Equity Analyst

  • That makes sense. And then my follow-up is just on persistency in Japan. I just noticed it fell below 94%, which is something we haven't seen in a while. Just wondering if you could unpack that a little bit. Is this lapse reissue related to the new cancer product? Or is there something else going on?

    這很合理。接著我的追問是關於日本的保單持續率(persistency)。我注意到它降到 94% 以下,這是我們一段時間沒看到的。想請你們多拆解一下:這是否與新癌症產品帶來的解約再投保(lapse reissue)有關?還是有其他因素?

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • I'll ask Todd to comment on it but you pretty much answered your own question. It has a lot to do with the introduction of cancer and natural replacement activity. Todd?

    我請 Todd 來說明,但你基本上已經回答了自己的問題。這很大程度與癌症產品的推出以及自然的替換活動有關。Todd?

  • James Todd Daniels - Executive VP, Director & CFO of Aflac Life Insurance Japan

    James Todd Daniels - Executive VP, Director & CFO of Aflac Life Insurance Japan

  • Yes. I think that we saw a lower lapse and reissue rate during the quarter than we did first quarter. And that's typical as we launch a new product, we expect that to wane over time, with the product being launched in the Japan Post channel. We did have some lapse and reissue activity during the quarter but it's within our expectation and it's still running somewhere around 50%.

    是的。我認為本季我們看到的解約再投保率比第一季更低。這在我們推出新產品時很典型;隨著時間推移,尤其是在日本郵政通路推出後,我們預期這種情況會逐步減弱。本季確實有一些解約再投保活動,但在我們的預期範圍內,目前仍大約在 50% 左右。

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • And Suneet, when you naturally have sales running lower than lapses, by definition, the age of the block increases. And when you have an older and more mature block, you're going to get higher lapses from it as well.

    而且,Suneet,當你的銷售自然低於解約量時,按定義,保單組合(block)的平均年齡就會上升。當你有一個更老、更成熟的保單組合時,解約也會更高。

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • One thing that I really like to add when we have this conversation, particularly spending some time in Japan and with the team is, we proactively promote the notion of an existing policyholder with an older cancer policy, replacing their policy if it's in their best interest, if it serves them economically and from a benefit and overall quality of coverage perspective. And we do that because it's good for the customer but we also do it because it brings that customer into our shops and allows for face-to-face interaction between our distribution partners and their clients and that often leads to cross-sell activity with the individual. But also cross-sell activity with their family members as the agents have a chance to engage. And so please realize that we don't actually look to avoid or curtail lapse and reissue activity. It's actually part of the strategy and it's particularly important on the cancer side, as you can imagine.

    在我們討論這個話題時,我很想補充一點,特別是我在日本與團隊相處一段時間後:我們會主動倡導一個觀念——若符合保戶的最佳利益,若從經濟性、給付以及整體保障品質的角度對他們更有利,我們會鼓勵持有較舊癌症保單的既有保戶進行保單替換。我們這麼做是因為這對客戶有利;同時也因為這能把客戶帶進我們的門市,讓我們的通路夥伴能與客戶面對面互動,而這往往會帶來對該客戶的交叉銷售機會;同時也會帶來對其家庭成員的交叉銷售,因為業務員有機會進一步接觸與交流。因此請理解,我們其實並不打算避免或抑制解約再投保活動。這本來就是策略的一部分,尤其在癌症產品方面,你可以想像其重要性。

  • Daniel Paul Amos - Chairman & CEO

    Daniel Paul Amos - Chairman & CEO

  • Look, to the next question. I'd like -- because we have Koide here from Japan, being President of Aflac's Japan, I just think it's important for him to say a couple of words because we had such a stellar performance with sales in banks. So Koide, would you just -- I'll ask the question, tell us how things are going in Japan.

    好,下一個問題。我想——因為今天日本這邊的 Koide 也在,他是 Aflac 日本的總裁——我認為讓他說幾句很重要,因為我們在銀行通路的銷售表現非常亮眼。所以 Koide,你能不能——我就直接問你:跟我們談談日本目前的情況如何?

  • Masatoshi Koide - President, CEO & Representative Director

    Masatoshi Koide - President, CEO & Representative Director

  • [Interpreted] As our sales results show, the cancer insurance product that we launched newly in August last year called, WINGS, is going extremely well. We now sell this cancer WINGS through all channels because we had somewhat a progressive launch of this product starting August last year with our associates. And then in January this year, Dai-ichi Life and bank channel has introduced it. And then in April of this year, the Japan Post has launched its product.

    [口譯] 如同我們的銷售結果所示,我們在去年 8 月新推出的癌症保險產品「WINGS」表現非常好。目前我們透過所有通路銷售這款癌症 WINGS,因為我們自去年 8 月起先由內部同仁逐步推進上市;接著在今年 1 月,第一生命與銀行通路導入;然後在今年 4 月,日本郵政也推出了該產品。

  • Well, all distribution channel sales has been very active surrounding this new cancer product. Because of the new product launch, it is obviously the case that things will become very active. But at the same time, the Japanese society, the economic activities have recovered during the same time. So with these 2 factors, I think the product has done extremely well.

    整體而言,各個通路圍繞這款新的癌症產品的銷售都非常活躍。由於新產品上市,活動變得更熱絡是理所當然的;但同時,日本社會與經濟活動也在同一期間復甦。因此在這兩個因素的帶動下,我認為這個產品的表現非常出色。

  • And our cancer -- new product competitiveness has increased as well. As Fred mentioned earlier, we now have this support service called Elisa (inaudible) cancer consultation service, which is somewhat of a concierge service for our customers. And by having this integrated with our cancer product, it is also pushing the sales as well.

    而我們的癌症——新產品競爭力也有所提升。正如Fred先前提到的,我們現在有一項支援服務,稱為Elisa(聽不清)癌症諮詢服務,對客戶而言有點像禮賓式服務。透過將此服務與我們的癌症產品整合,也同樣帶動了銷售。

  • We are also preparing to launch a new medical product with very good competitiveness in September. So as a result of all these things that are going well, all our employees in Aflac Japan as well as our salespeople in our distribution channel, of all channels are extremely motivated to do more sales.

    我們也正準備在9月推出一款競爭力非常強的新醫療產品。因此,隨著這些進展都相當順利,Aflac Japan的全體員工以及我們各個通路的業務人員都非常有動力,想要進一步提升銷售。

  • Operator

    Operator

  • Our next question will come from Wes Carmichael with Wells Fargo.

    下一個問題來自Wells Fargo的Wes Carmichael。

  • Wesley Collin Carmichael - VP & Equity Analyst

    Wesley Collin Carmichael - VP & Equity Analyst

  • Hoping you could just talk a little bit about the lapse and persistency trends in Aflac U.S. It looks like it's improving a bit. But maybe you could help us, what's your expectations for -- how that should trend from here? And maybe any impact on the expense ratios. I think that's been a little bit elevated by lapses.

    希望你能談談Aflac美國在解約率與保單持續率(persistency)的趨勢。看起來似乎有些改善。但也許你能協助我們了解,你對於——接下來這個趨勢的預期為何?以及對費用率可能的影響。我認為費用率有點被解約所拉高。

  • Virgil Raynard Miller - President of Aflac U.S.

    Virgil Raynard Miller - President of Aflac U.S.

  • This is Virgil. Let me first say that I'm pleased with the stabilization that you see, that's occurring in our persistency rate. So this quarter, we came in at 78.2%. It's about 10 basis points higher than last year. I mentioned in Q1, we have done quite a few conservative efforts to go after this. We have stood up, what I call, the [offense] of the persistency, which is really a team of data scientists that spend 24 hours a day looking at different efforts that we can really do. So I think that you're going to see even more to come from that. Today, what you heard me say earlier is mainly about driving utilization. We're really pushing out campaigns with wellness. What we did in Q1 and Q2 was more of a shotgun approach reminding everyone that has those benefits within those policies to go out and file those wellness claims, which you'll see us doing going forward now is more of a, what I would call, a more strategic or surgical attack, which is around event-driven notifications.

    我是Virgil。我先說,我對你所看到的保單持續率趨於穩定感到滿意。本季我們是78.2%,比去年高約10個基點。我在第一季提到,我們做了不少偏保守的努力來改善這件事。我們成立了我所稱的保單持續率「進攻」團隊,實際上是一支資料科學家團隊,24小時不間斷地研究我們可以真正採取的各種措施。所以我認為你會看到更多成果。今天你先前聽到我說的,主要是關於提升使用率。我們正大力推動健康(wellness)相關活動。我們在第一季與第二季做的比較像是散彈槍式作法,提醒所有在保單中擁有那些給付的人去申請健康理賠;而你接下來會看到我們更偏向我所說的、更具策略性或更精準的作法,也就是以事件驅動的通知為核心。

  • For example, if someone recently got married or they have a birthday, we would be reaching out to them and remind them to utilize those benefits that we have. Overall, you saw that the persistency plus the 6.4% increase we had in U.S. sales drove to higher earned premiums for us. The earned premium rate was up about 2.2% and that's really what's helping right now, the growth, is what's happened to balance off our expense ratios. We still see higher expenses right now with our investments and our growth initiatives. But those growth initiatives, again contributed to about 4% to 8% growth in the second quarter toward our revenue.

    例如,如果有人最近結婚或過生日,我們就會主動聯繫並提醒他們使用我們提供的那些給付。整體而言,你看到保單持續率的改善,加上我們美國銷售成長6.4%,帶動了更高的已賺保費。已賺保費成長率約為2.2%,而這正是目前支撐成長、並有助於抵銷費用率壓力的關鍵。我們目前仍看到較高的費用,主要來自投資以及成長計畫。但這些成長計畫同樣在第二季對我們的營收貢獻了約4%到8%的成長。

  • Let me just ask Steve Beaver, our CFO in the U.S. if he wants to comment any further.

    我請Steve Beaver——我們美國的財務長——看看是否要再補充說明。

  • Steven Kent Beaver - Senior VP & CFO of Aflac U.S.

    Steven Kent Beaver - Senior VP & CFO of Aflac U.S.

  • I would just add that, remember, that the activity around driving persistency takes time to emerge in that 12-month rolling metric. But we do expect, like Max said in his video, to help us bend that curve and lower the expense ratio going forward.

    我只想補充,請記得,推動保單持續率的相關活動,需要時間才會在那個12個月滾動指標中顯現。但我們確實預期,如同Max在影片中所說,這將有助於我們讓曲線轉折,並在未來降低費用率。

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • And whilst the impact on the second quarter expense ratio from higher-than-normal [de-commoditization] was about 50 basis points.

    此外,第二季費用率受到高於正常水準的[去商品化]影響約為50個基點。

  • Wesley Collin Carmichael - VP & Equity Analyst

    Wesley Collin Carmichael - VP & Equity Analyst

  • Got it. Very helpful. And then on -- I just wanted to kind of clarify maybe a follow-up to Tom's question but on net earned premium growth in Japan, I think it was impacted by 260 basis points related to the reinsurance transaction and some lapses. I just want to clarify, for the rest of 2023, do you think that roughly 6-ish percent decline is reasonable for the full year and then it kind of moves back into that 1.5% to 2% -- 2.5% decline in 2024. Just wanted your thoughts around that.

    了解。非常有幫助。接著關於——我想釐清一下,可能是Tom問題的延伸,但關於日本的淨已賺保費成長,我認為其中有260個基點受到再保交易以及一些解約的影響。我想確認一下,對於2023年剩餘期間,你是否認為全年大約下滑6%左右是合理的,然後在2024年回到下滑1.5%到2%——2.5%的區間?想聽聽你的看法。

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • So the impact from reinsurance will continue throughout the year and I would expect it to be running up at that level. The impact from paid-up and the DPL impact was rather high in this quarter. It's going to be quite a volatile number overall. But I would just note that it was -- we deem it to be quite high this quarter.

    再保的影響會持續整個年度,我預期會大致維持在那個水準。至於繳清(paid-up)以及DPL的影響,本季相對偏高。整體而言,這會是一個波動相當大的數字。但我只想指出——我們認為本季確實偏高。

  • Operator

    Operator

  • Our next question will come from Jimmy Bhullar with JPMorgan.

    下一個問題來自JPMorgan的Jimmy Bhullar。

  • Jamminder Singh Bhullar - Senior Analyst

    Jamminder Singh Bhullar - Senior Analyst

  • So first, just a question on the upcoming launch of the medical product in mid-September. Should we assume that going into that sales of medical policies will be depressed as agents are sort of waiting for the new product to be rolled out? Or is that already in your numbers in 2Q as well?

    首先,關於9月中旬即將推出的醫療產品。我們是否應該假設,在推出前,醫療保單的銷售會受到壓抑,因為業務員可能在等待新產品上市?還是說這種情況在第二季的數字裡也已經反映了?

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • Well, we have our team here in Japan comment on that. So Yoshizumi-san, the question is, is there a natural pullback in medical when there's anticipation of a new medical product to come later in the year?

    我們請日本團隊來回應。所以Yoshizumi先生,問題是:當市場預期年底會推出新的醫療產品時,醫療商品是否會出現自然的回落?

  • Koichiro Yoshizumi - EVP of Sales & Mrkt. and Director of Sales, Mrkt., Alliance Strategy - Aflac Life Insurance Japan

    Koichiro Yoshizumi - EVP of Sales & Mrkt. and Director of Sales, Mrkt., Alliance Strategy - Aflac Life Insurance Japan

  • [Interpreted] Fred, thank you. I'll answer the question. So since we are selling our products in multichannel, let me start out with the associates channel. In the associates channel, as we launch our medical product soon, what I need to talk about is the cancer product that we launched in August last year. And since the cancer product will have gone around a cycle of a year, that sales will go down. But then, when we look at other channels that only sell cancer products such as the Japan Post channel, Dai-ichi Life channel and Daido Life, it will not have been a year since they launched new cancer WINGS and there should not be any impact on medical insurance, sorry, there should not be any impact on cancer sales from the medical launch.

    [口譯] Fred,謝謝。我來回答這個問題。由於我們透過多通路銷售產品,我先從業務員(associates)通路談起。在業務員通路,因為我們即將推出醫療產品,我需要先談談我們去年8月推出的癌症產品。由於癌症產品已經走完一年的週期,銷售會下滑。不過,當我們看其他只銷售癌症產品的通路,例如日本郵政通路、第一生命通路以及大同生命,距離他們推出新的癌症WINGS尚未滿一年,因此醫療保險的推出不會對癌症銷售造成影響——抱歉,應該說,醫療產品上市不會對癌症銷售造成影響。

  • Daniel Paul Amos - Chairman & CEO

    Daniel Paul Amos - Chairman & CEO

  • Let me just make a comment. This is Dan. Is that anytime we come out with a new product, it always has some impact. So we're taking that as being a standard, no matter what. If it's a new cancer, it affects medical, if it's a new medical, it's cancer because everyone goes to the easiest thing to sell. And so something new and sparkly always looks better. So that's going to always happen. But the variation can be such. But all in all, that's part of the system. That's why we're constantly having to upgrade, is because we have to show -- the competitors come out with new things, we have to come out with new things. But because it isn't actual expenses but fixed cost, we have to do this.

    我補充一下。我是Dan。只要我們推出新產品,總是會有一些影響。所以我們把這視為常態,無論如何都會發生。如果是新的癌症產品,會影響醫療;如果是新的醫療產品,也會影響癌症,因為大家都會先去賣最容易賣的東西。新的、看起來更吸引人的產品總是更好賣,所以這種情況一定會發生,只是幅度可能不同。但總體而言,這是體系的一部分。這也是為什麼我們必須持續升級,因為競爭對手會推出新東西,我們也必須推出新東西。但由於這不是變動費用而是固定成本,我們必須這麼做。

  • Jamminder Singh Bhullar - Senior Analyst

    Jamminder Singh Bhullar - Senior Analyst

  • And then as you think of longer term, the alliance with the Post, what's your view on the likelihood of that being expanded beyond just cancer? Or do you think it's unlikely given that they've already got other providers for some of the other products?

    再從較長期來看,與郵政的聯盟,你對於將合作擴大到不只癌症的可能性有何看法?還是你認為不太可能,因為他們在其他一些產品上已經有其他供應商?

  • Daniel Paul Amos - Chairman & CEO

    Daniel Paul Amos - Chairman & CEO

  • Well, I don't think you ever say never. And you also remember that they're our largest shareholder. Those are positive things that we'll look at going forward. Fred, you got any comments?

    我想你永遠不會說不可能。而且你也要記得,他們是我們最大的股東。這些都是我們未來會持續評估的正面因素。Fred,你有什麼補充嗎?

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • No. I agree, Dan. I think right now, what we focus on is just expanding within the line of cancer, meaning, so when looking at refreshing our cancer product, we also have lump sum critical illness that we include. We also has, as I mentioned earlier, the (inaudible) cancer consulting service. And so quite honestly, what we're focusing on now with Japan Post is not just cancer sales but how do we expand and enrich the overall activity within that cancer line of business. So I think what you can assume is, anything that comes out or any developments or innovation around the cancer line of business that we will certainly deploy that within the Japan Post system.

    沒有。我同意,Dan。我認為目前我們專注的是在癌症這條產品線內擴張。也就是說,在更新我們的癌症產品時,我們也納入一次給付型重大疾病(lump sum critical illness)。另外,如我先前提到的,我們也有(聽不清)的癌症諮詢服務。坦白說,我們目前與日本郵政合作的重點,不只是癌症銷售本身,而是如何在癌症這條業務線中擴大並豐富整體活動。因此你可以假設,任何在癌症業務線上的新推出、發展或創新,我們都一定會在日本郵政體系中加以部署。

  • Operator

    Operator

  • And our next question will come from Josh Shanker with Bank of America.

    下一個問題來自美國銀行的Josh Shanker。

  • Joshua David Shanker - MD

    Joshua David Shanker - MD

  • Looking at the turnaround in premium growth in the U.S., it's very favorable. Is there any senior management type compensation to support the turnaround growth specifically at the company?

    從美國保費成長的回升來看,表現非常有利。公司是否有任何高階管理層類型的薪酬機制,專門用來支持這項成長回升?

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • Essentially, total of a -- both senior management and employees have incentive compensation based on earned premium.

    基本上,總體而言——高階管理層與員工的激勵性薪酬,都是以已賺保費為基礎。

  • Joshua David Shanker - MD

    Joshua David Shanker - MD

  • And is that targeted? Is there any -- can you go into how that works a little bit?

    那是有目標設定的嗎?是否有任何——你能稍微說明一下它是如何運作的嗎?

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • You mean in terms of specific levels?

    你是指特定的級距水準嗎?

  • Joshua David Shanker - MD

    Joshua David Shanker - MD

  • Is it above a certain target, there's a long-term compensation grant? Is there a trajectory? How should we think about how invested the company is in growing premium?

    是否在高於某個目標之上,就會有長期薪酬授予?是否有一條成長軌跡?我們應該如何看待公司在推動保費成長上的投入程度?

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • In the short term, it's outlined in our proxy and you can see our MIP targets there.

    短期方面,我們在委託書(proxy)中有說明,你可以在那裡看到我們的 MIP 目標。

  • Joshua David Shanker - MD

    Joshua David Shanker - MD

  • Okay. And that's true for both the Japan business and the U.S. business?

    好的。那日本業務與美國業務都是如此嗎?

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • That is correct.

    沒錯。

  • Daniel Paul Amos - Chairman & CEO

    Daniel Paul Amos - Chairman & CEO

  • We try our best to keep these tied together to our bonuses to where, when you're happy, we're happy, when we're happy, you're happy. So if you look at those, you will see that that's a very important part of our Board function under the Compensation Committee that will tie that together.

    我們盡力把這些與獎金連結在一起,讓你高興時我們也高興、我們高興時你也高興。所以如果你去看那些內容,你會看到在董事會的薪酬委員會職能之下,這是非常重要的一部分,會把這些連結起來。

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • You'll see very clearly in each segment, U.S. and Japan, there's both sales and earned premium targets. And then as you can imagine, we cascade that down and get more particular by line of business when we get down to executives or officers that are in charge more directly to a particular line of business. So the concept of earned premium is an essential piece of how we compensate.

    你會很清楚地看到,在每個事業部(美國與日本)都有銷售與已賺保費的目標。然後如你所想,我們會把這些目標層層下達,當落到更直接負責某一特定業務線的高階主管或主管人員時,會依業務線更具體化。因此,「已賺保費」的概念是我們薪酬制度中的核心要素。

  • Max Kristian Broden - Executive VP & CFO

    Max Kristian Broden - Executive VP & CFO

  • And Josh, I would just remind you that the earned premium outlook that we gave for the year 2023 and 2024 is a CAGR of 3% to 5% earned premium growth.

    Josh,我也想提醒你,我們對 2023 年與 2024 年所給出的已賺保費展望,是已賺保費成長 3% 到 5% 的年複合成長率(CAGR)。

  • Joshua David Shanker - MD

    Joshua David Shanker - MD

  • Yes. I do. I am aware of that.

    是的,我知道。我了解那一點。

  • Operator

    Operator

  • Our next question will come from Mark Hughes with Truist Securities.

    下一個問題來自 Truist Securities 的 Mark Hughes。

  • Unidentified Analyst

    Unidentified Analyst

  • This is actually Maxwell (inaudible). I am calling on behalf of Mark Hughes. So looking at the total recruited agent count, it looks like it reduced 4% year-over-year on a tough comp, though and up 6% sequentially. I was just wondering if you could give me an outlook or what the environment looks like for recruiting and the labor market right now.

    我其實是 Maxwell(聽不清),我代表 Mark Hughes 來提問。就總招募代理人數來看,在一個艱難的比較基期下,年減 4%,但季增 6%。我想請問你能否提供一下招募的展望,或目前招募環境與勞動市場的情況?

  • Virgil Raynard Miller - President of Aflac U.S.

    Virgil Raynard Miller - President of Aflac U.S.

  • This is Virgil from the U.S. Actually, I would tell you, I'm sitting very pleased with our performance for the first half of the year. To your point, we did see a decline in the second quarter. But if you look at the (inaudible) some of the numbers, I look at the lead indicators, we had strong recruitment in January, February, March, April and May. The decline really happened in June. If you look at for the first 6 months, so we're sitting at about 8% up. If you look at the actual career agents themselves, we had a strong increase in that Q1 at about 35%. So we're sitting about -- will not be specific on a number. We've got about 600 more than I really expected this time of the year.

    我是美國這邊的 Virgil。其實我會說,我對我們上半年表現感到非常滿意。正如你所說,我們在第二季確實看到下滑。但如果你看(聽不清)的一些數字,我會看領先指標:我們在 1、2、3、4、5 月的招募都很強勁;下滑主要發生在 6 月。若看前 6 個月,我們大約成長 8%。若看實際的職涯型代理人(career agents),我們在第一季大幅增加,約 35%。所以我們目前大約——我不會講一個具體數字——但比我在這個時間點原本預期的多了大約 600 人。

  • What it really means to me, though, is we've got a great opportunity, which we did in June to really push on productivity conversions. We have first year conversions up 5.2% and then really driving to our average weekly producers. So average weekly producer number is up again for the quarter, over 2%. That's really what we're trying to do. We're bringing them into the pipeline. We're getting quality recruits. We're giving them converted. We happen to drive productivity and then we're looking to turn them into average weekly producer, so I would tell you that recruiting is favorable for the remainder of the year. We really don't see any major headwinds out there. But we will take those recruit, convert them and give them average weekly producer. So looking forward to a even stronger second half of the year.

    不過,這對我真正的意義是:我們有很好的機會——我們在 6 月也確實這麼做——去更用力推動生產力的轉換。我們的首年轉換率提升了 5.2%,並且持續推動平均每週生產者(average weekly producers)。平均每週生產者的數字在本季又上升了,超過 2%。這正是我們想做的:把人帶進管道、招到高品質的人才、讓他們完成轉換、推動生產力,然後把他們培養成平均每週生產者。因此我會說,今年剩餘期間招募環境是有利的,我們沒有看到任何重大的逆風。但我們會把這些招募進來的人轉換並培養成平均每週生產者。期待下半年會更強勁。

  • Daniel Paul Amos - Chairman & CEO

    Daniel Paul Amos - Chairman & CEO

  • Let me make a comment about recruiting from the past. And we have to remember, we're in a postpandemic period. But our track record for the past has been that with high unemployment, people tend to come selling for us because they can't get a job on a sal. So they're working on commission. That's not limited to Aflac. Anybody that's in that business. Most people prefer a salary with a bonus versus all commission.

    我想就過去的招募補充一點。我們必須記得,我們正處於後疫情時期。但我們過去的經驗是:在高失業率時,人們往往會來替我們做銷售,因為他們找不到一份有薪資的工作,所以就做以佣金為主的工作。這不僅限於 Aflac,任何在這個行業的人都一樣。大多數人更偏好「固定薪資加獎金」,而不是「全佣金」。

  • So that's the first point. But on the other hand, when you have high unemployment, recruiting becomes more difficult. But at the workplace, there are more people to enroll. So the people that are selling are seeing more people at the worksite. It will be interesting, what happens here is, we see more people working from home. We're seeing that they're -- I was in a restaurant the other day that it was closed for lunch because they couldn't get enough people to work there.

    這是第一點。但另一方面,當失業率高時,招募會變得更困難。不過在職場端,能夠進行投保登記(enroll)的人會更多。所以從事銷售的人在工作場所會接觸到更多人。接下來會很有意思的是:我們看到更多人在家工作。我前幾天去一家餐廳,它中午不營業,因為找不到足夠的人來上班。

  • So these things are happening and we're having to do that. But I would say, considering that it's hard to find employees certainly at the lower levels, it tells you that we're doing a pretty good job. And I give kudos to Virgil and their team for what they're doing because it is a little bit uncharted waters because the tradition or the way we've been doing it, I've just got to see how it falls out. So I want to make that comment.

    所以這些事情正在發生,我們也必須因應。但我會說,考量到確實很難找到員工、尤其是在較基層的職位,這也顯示我們做得相當不錯。我也要稱讚 Virgil 和他的團隊,因為這確實有點像在未知水域航行;傳統上或我們過去的做法——我得看看最後會如何發展。所以我想補充這點。

  • Virgil Raynard Miller - President of Aflac U.S.

    Virgil Raynard Miller - President of Aflac U.S.

  • Yes. To that point, Dan, we have that baked into our numbers. So that's what I mean when I say we're on target with our expectations. I mentioned in Q1, you won't see these humungous numbers that you see in the past, right? We've got -- and that's why you see a concerted effort on making sure we convert what we have. And it's going pretty well for us this year.

    是的,Dan,針對你剛才那點,我們已把這些因素納入我們的數字假設中。這就是我說我們符合預期目標的原因。我在第一季提過,你不會再看到過去那種非常龐大的數字,對吧?我們——也因此你會看到我們更有意識地確保把現有的人轉換好。而今年到目前為止,對我們來說進展相當順利。

  • Frederick John Crawford - President & COO

    Frederick John Crawford - President & COO

  • If we could for a minute before we go to the next question, Jimmy had asked a question earlier about our expansion opportunities in Japan Post. And as Dan mentioned, our President, Koide-san, is here with us today this morning in Columbus. And he would like to add just a few comments about the Japan Post alliance. Koide-san?

    在我們進入下一個問題之前,我想先花一分鐘:Jimmy 先前問到我們在日本郵政(Japan Post)的擴張機會。正如 Dan 提到的,我們的總裁 Koide 先生今天早上也在哥倫布與我們同在,他想就日本郵政的合作聯盟再補充幾點。Koide 先生?

  • Masatoshi Koide - President, CEO & Representative Director

    Masatoshi Koide - President, CEO & Representative Director

  • [Interpreted] This is Koide once again. Let me just add a little bit on what we are doing with the Japan Post Group or the Japan Post Insurance. We are actually doing a lot of collaboration in various areas. For example, apart from the cancer insurance sales, we are also working with the Japan Post Insurance Group to have concierge service on nursing care area. And on top of that, we are also doing some start-up acceleration program together with the Japan Post Insurance Group. So as you can see, we are working with the Japan Post Group outside of cancer insurance area as well. That's all.

    [口譯] 我是 Koide,再次發言。我想就我們與日本郵政集團或日本郵政保險的合作,再補充一點。我們其實在多個領域進行了大量協作。舉例來說,除了癌症保險的銷售之外,我們也與日本郵政保險集團合作,在長照領域提供禮賓服務(concierge service)。此外,我們也與日本郵政保險集團共同推動一些新創加速計畫(start-up acceleration program)。因此如各位所見,我們與日本郵政集團的合作也不僅限於癌症保險領域。以上。

  • David Young

    David Young

  • All right, Joe. I believe that's the...

    好的,Joe。我相信那就是……

  • Operator

    Operator

  • This concludes our question-and-answer session. I'd like to turn the conference back over to David Young for any closing remarks.

    問答環節到此結束。接下來我想把電話會議交回給 David Young,請他做結語。

  • David Young

    David Young

  • Thank you, Joe. That concludes our call. I want to thank you all for joining us this morning. Please reach out to the Investor Relations team if you have any questions and we look forward to speaking with you soon and wish you all continued good health. Thank you.

    謝謝你,Joe。本次電話會議到此結束。感謝各位今天早上參與。若有任何問題,請與投資人關係團隊聯繫;我們也期待很快再與各位交流,並祝各位持續健康。謝謝。

  • Operator

    Operator

  • The conference has now concluded. Thank you very much for attending today's presentation. You may now disconnect your lines.

    本次會議現已結束。非常感謝各位出席今天的簡報。您現在可以掛斷電話線。

  • [Portions of this transcript that are marked [Interpreted] were spoken by an interpreter present on the live call.]

    [本逐字稿中標示為 [Interpreted] 的部分,係由現場電話會議中的口譯員所口譯。]